看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。 |8 W0 Q& j) W0 [7 Y3 E
" t$ C# ^$ _& ]% e0 e; R: Y, X0 V
Currently available feasibility data for possible combination strategies. ( O# b! v1 R, i! ]3 K
————————————————————————————————+ d" Y( p3 V9 l/ m3 `
Combination Feasibility according to preliminary data ! M- A+ L( o1 b
——————————————————————————————————: Q. R$ g2 W! e7 R7 W
Bevacizumab + sorafenib Yes, reduced dose
8 L9 k; X: z& C, z- M9 z$ XBevacizumab + sunitinib† No 4 n* }. \" E. j+ i6 N0 J) ^( k# l
Bevacizumab + temsirolimus Yes ) s8 Y2 s9 y$ {. l) w% a S
Bevacizumab + everolimus Yes
$ G- S8 C& q' p% \( f; VSorafenib + sunitinib ? 5 v3 F7 x$ l8 P, u' G, J
Sorafenib + temsirolimus Yes, reduced dose ( v: a1 v. @. Y1 Z8 w
Sorafenib + everolimus Yes, reduced dose 0 N0 z, u! L" s# n# Y
Sunitinib + temsirolimus† No " i$ G" \4 A: x# c
Sunitinib + everolimus ?
0 j. ^ F$ [6 e7 z7 l QTemsirolimus + everolimus ? 0 C- Q: q4 E9 K+ K8 l: F6 d N
————————————————————
/ @ q8 a7 M4 Q†Led to US FDA warning.
# ?2 S0 K4 j7 o; Q5 x$ w; A?: As yet unattempted combination.; X5 i3 f9 c% a: a9 ]0 K+ V
|